Manuscript no. HAEMATOL /2011/056135 entitled "IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol"

Authors: Petra Dörge, Barbara Meissner, Martin Zimmermann, Anja Möricke, André Schrauder, Jean-Pierre Bouquin, Denis Schewe, Jochen Harbott, Andrea Teigler-Schlegel, Richard Ratei, Wolf-Dieter Ludwig, Rolf Koehler, Claus R. Bartram, Martin Schrappe, Martin Stanulla, Gunnar Cario

Information about the contributions of each person named as having participated in the study

1) Guarantor(s), i.e., person(s) who is (are) responsible for the integrity of the work as a whole: • Petra Dörge, Martin Zimmermann and Martin Stanulla had full access to all data and are responsible for the integrity of the presented work

According to the International Committee of Medical Journal Editors (ICMJE) (http://www.icmje.org/ethical_1author.html): "Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3 Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship".

The guarantors of this manuscript confirm that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

2) Authors who participated in the conception of the study:

Martin Stanulla, Gunnar Cario, Martin Schrappe

- 3) Design & Methods. The following authors were responsible for specific investigations:
- Petra Dörge was responsible for MLPA analysis
- Rolf Koehler, André Schrauder and Claus R. Bartram performed MRD analysis
- Jochen Harbott and Andrea Teigler Schlegel performed cytogenetic investigations
- Barbara Meissner, Denis Schewe and Jean-Pierre Bourguin made initial observations on IKZF1 aberrations
- Martin Zimmermann, Petra Dörge, Martin Schrappe, Martin Stanulla, and Anja Möricke performed statistical analysis and/or contributed clinical data
- Richard Ratei and Wolf-Dieter Ludwig performed immunophenotyping of leukemias
- 4) Results. The following authors were responsible for specific portions of the results, including figures and tables:
- Petra Dörge together with Barbara Meissner, Gunnar Cario and Martin Stanulla was responsible for results obtained by MLPA analysis (table 1, supplementary figures 1 & 2)
- Rolf Koehler, André Schrauder and Claus R. Bartram are responsible for MRD analysis (table 2, supplementary table 1)
- Jochen Harbott and Andrea Teigler Schlegel are responsible for cytogenetic results in table 2 and supplementary tables 1 to 4
- Gunnar Cario, Martin Stanulla, Jean-Pierre Bourquin, Denis Schewe and Martin Schrappe are responsible for information on P2RY8-CRLF2 (supplementary tables 3 and 4)
- Martin Zimmermann (figure 1, supplementary tables 2 to 4), Petra Dörge, Martin Schrappe, Anja Möricke, Gunnar Cario and Martin Stanulla (table 2, supplementary tables) performed statistical analysis and/or interpreted statistical results

• Richard Ratei and Wolf-Dieter Ludwig are responsible for immunophenotyping results of leukemias (table 2, supplementary tables 1 and 2)

5) Writing the manuscript. The following authors were responsible for writing the manuscript:

- Petra Dörge, Martin Stanulla and Gunnar Cario drafted the manuscript
- P Barbara Meissner, Martin Zimmermann, Anja Möricke, André Schrauder, Jean-Pierre Bouquin, Denis Schewe, Jochen Harbott, Andrea Teigler-Schlegel, Richard Ratei, Wolf-Dieter Ludwig, Rolf Koehler, Claus R. Bartram and Martin Schrappe critically read and modified the manuscript and finally all authors approved it in the end

6) Contributors Listed in Acknowledgments:

• Birthe Fedders, Kristina Wulf and Christian Bretscher from the ALL-BFM laboratory provided excellent technical assistance (nucleic acid preparation, MLPA, etc.) as did our colleagues from the sequencing facility at the Institute for Clinical Molecular Biology at the University Hospital Schleswig-Holstein, Campus Kiel